CommercialCoverageMedium impact
08.01.33l, Leuprolide (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)
Independence Blue Cross·Oncology, Endocrinology, Urology +1 more·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated their medical necessity criteria and general guidelines for Leuprolide medications (Camcevi, Eligard, Fensolvi, Lupron Depot) effective December 29, 2025. This appears to be an informational update to existing coverage policies for these hormone therapy medications.
Action Required
By December 29, 2025: Review updated medical necessity criteria for Leuprolide medications (Camcevi, Eligard, Fensolvi, Lupron Depot) at the source URL. Providers should ensure documentation meets revised guidelines for these medications. Update prior authorization requests to align with new medical necessity requirements.